Idorsia Pharmaceuticals Deal History & Licensing Activity
Idorsia Pharmaceuticals is a biotech headquartered in Switzerland. Over the past three years, Idorsia Pharmaceuticals has been involved in 3 licensing and acquisition transactions, with a primary focus on Small Molecules (4 deals). The company currently has 18 active clinical trials, primarily in Rare Disease.
Deals (12mo)
2
Active Trials
18
Top Modality
Small Molecules
Focus Area
Rare Disease
Idorsia Pharmaceuticals Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Idorsia Pharmaceuticals in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| QUVIVIQ (daridorexant) | Jamjoom Pharmaceuticals Factory Co. | Small Molecules | Approved | license | Jul 27, 2026 |
| QUVIVIQ | Pharmalink Drug Store L.L.C | Small Molecules | Approved | license | Mar 10, 2026 |
Idorsia Pharmaceuticals Pipeline Focus
Therapeutic areas and modalities where Idorsia Pharmaceuticals is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Idorsia Pharmaceuticals Clinical Pipeline
Idorsia Pharmaceuticals has 18 active clinical trials across 4 development phases.
7
Unknown
2
Phase 4
4
Phase 2
5
Phase 3
See How Your Asset Matches Idorsia Pharmaceuticals's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Idorsia Pharmaceuticals Licensing & Deal Activity
Idorsia Pharmaceuticals is a biotech company based in Switzerland that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Idorsia Pharmaceuticals ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Idorsia Pharmaceuticals include Rare Disease (5 deals and trials), CNS Disorders (5 deals and trials), Neurology (4 deals and trials), and Cardiovascular (3 deals and trials). In terms of modality, Idorsia Pharmaceuticals has shown particular interest in small molecules, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Idorsia Pharmaceuticals and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Idorsia Pharmaceuticals's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.